Drago F, Turchetta A, Guccione P, Santilli A, Pompei E, Gagliardi M G, Calzolari A, Ragonese P
Dipartimento Medico Chirurgico di Cardiologia Pediatrica, Ospedale Pediatrico Bambino Gesù, Roma.
G Ital Cardiol. 1995 Jan;25(1):11-6.
The aim of the study was the evaluation of the usefulness of transesophageal atrial pacing in predicting chronic oral treatment efficacy of symptomatic reciprocating supraventricular tachycardia in infants and in avoiding the risk of very dangerous recurrences at home.
We studied 13 infants (11 males, 2 females, mean age 43 +/- 31 days) with symptomatic reciprocating supraventricular tachycardia and no structural heart disease. All patients had chronic oral therapy, using the drug effective in acute i.v. somministration. Each patient was discharged when supraventricular tachycardia was not inducible with transesophageal atrial pacing after 5 half-lives of the drug used in chronic oral treatment. All patients, every 6 months, were retested with transesophageal atrial pacing alternatively during chronic oral therapy and after complete wash out. Oral therapy was stopped in each patient when supraventricular tachycardia was not inducible after the wash out.
The number of oral treatments tested for each patient were 2 +/- 1 (range 1-5). The number of transesophageal studies performed for each patient were 4 +/- 2 (range 3-7). No patient had symptomatic episodes of supraventricular tachycardia or needed to change therapy during the follow-up. The oral treatment was stopped after the twelfth month of life in 8 patients and after the twenty-fourth in 2 others without recurrences.
Transesophageal atrial pacing seems to be useful in predicting accurately and rapidly the oral treatment efficacy of supraventricular tachycardia in infants. Our protocol seems to be effective to avoid dangerous recurrences of tachycardia and to decide when we can stop therapy without risk.
本研究的目的是评估经食管心房起搏在预测婴儿症状性折返性室上性心动过速的慢性口服治疗疗效以及避免在家中发生非常危险的复发风险方面的实用性。
我们研究了13例患有症状性折返性室上性心动过速且无结构性心脏病的婴儿(11例男性,2例女性,平均年龄43±31天)。所有患者均接受慢性口服治疗,使用在急性静脉给药时有效的药物。在慢性口服治疗中使用的药物经过5个半衰期后,经食管心房起搏不能诱发室上性心动过速时,每个患者出院。在慢性口服治疗期间以及完全洗脱后,所有患者每6个月交替进行经食管心房起搏重新检测。当洗脱后不能诱发室上性心动过速时,停止每个患者的口服治疗。
每个患者测试的口服治疗次数为2±1(范围1 - 5)。每个患者进行的经食管研究次数为4±2(范围3 - 7)。在随访期间,没有患者出现症状性室上性心动过速发作或需要改变治疗。8例患者在出生后第12个月停止口服治疗,另外2例在第24个月停止治疗,均无复发。
经食管心房起搏似乎有助于准确、快速地预测婴儿室上性心动过速的口服治疗疗效。我们的方案似乎有效地避免了心动过速的危险复发,并确定何时可以无风险地停止治疗。